The US is the bigger Epilepsy Drugs market: $4 Bn against $768 Mn in 2023, about 5.3 times as large.
Canada grows faster: 3.5% a year, against 1.5%. The gap still grows from $3.3 Bn to $3.6 Bn by 2033.
Clinical research: 224 active trials in the US, 23 in Canada.
| Measure |  US |  Canada |
|---|---|---|
| Market size, 2023 | $4 Bn | $768 Mn |
| Market size, 2033 projected | $4.7 Bn | $1.1 Bn |
| Growth a year (CAGR) | 1.5% | 3.5% |
| Money added, 2023–2033 | $647 Mn | $315 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $12 | $18 |
| Active clinical trials | 224 | 23 |
| Full report | US report | Canada report |
Year by year, 2023 to 2033
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Epilepsy Drugs, US or Canada?
The US is the bigger Epilepsy Drugs market: $4 Bn against $768 Mn in 2023, about 5.3 times as large.
Which grows faster in Epilepsy Drugs, US or Canada?
Canada grows faster: 3.5% a year, against 1.5%. The gap still grows from $3.3 Bn to $3.6 Bn by 2033.
More Epilepsy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.